This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Orgenesis’s 8K filing here.
Orgenesis Company Profile
Orgenesis Inc, a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Featured Stories
- Five stocks we like better than Orgenesis
- What is a Bond Market Holiday? How to Invest and Trade
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- What Does the Future Hold for Eli Lilly?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
